Michael Lehmicke, Senior Director of Science & Industry Affairs, Alliance for Regenerative Medicine, Washington, D.C., talks on the growing interest in developing technologies to improve cell and gene therapy manufacturing, notably in implementing automated processes. Mr Lehmicke emphasizes the importance of standardizing these processes. This interview took place at Advanced Therapies Week 2022.
Disclosures
Michael Lehmicke is the Senior Director of Science & Industry Affairs at Alliance for Regenerative Medicine.